Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-29T00:24:10.305Z Has data issue: false hasContentIssue false
  • English
  • Français

Major depression is a serious and potentially fatal brain syndrome requiring pharmacotherapy or neuromodulation, and psychotherapy

Published online by Cambridge University Press:  03 May 2022

Joseph F. Goldberg Open the ORCID record for Joseph F. Goldberg [Opens in a new window]  and
Henry A. Nasrallah
Joseph F. Goldberg*
Affiliation:
Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Henry A. Nasrallah
Affiliation:
Department of Psychiatry, University of Cincinnati, Cincinnati, OH, USA
*
Author for correspondence: Joseph F. Goldberg, E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

Antidepressantselectroconvulsive therapymajor depressive disorderneuromodulationpharmacotherapy
Type
Commentary
Information
Psychological Medicine , Volume 52 , Issue 8 , June 2022 , pp. 1423 - 1425
Check for updates
Copyright
Copyright © The Author(s), 2022. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

*

Additional references are available upon request from the authors.

References

References*

Anderson, K. M., Collins, M. A., Kong, R., Fang, K., Li, J., He, T., … Holmes, A. J. (2020). Convergent molecular, cellular, and cortical neuroimaging signatures of major depressive disorder. Proceedings of the National Academy of Sciences, 177, 25138–25149. doi: 10.1073/pnas.2008004117. Epub 2020 Sep 21.CrossRefGoogle Scholar
Citrome, L. (2016). Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders, 196, 225–233. doi: 10.1016/j.jad.2016.02.042. Epub 2016 Feb 18.CrossRefGoogle ScholarPubMed
Goldapple, K., Segal, A., Garson, C., Lau, M., Bieling, P., Kennedy, S., & Mayberg, H. (2004). Modulation of cortical-limbic pathways in major depression: Treatment-specific effects of cognitive behavior therapy. Archives of General Psychiatry, 61, 34–41. doi: 10.1001/archpsyc.61.1.34CrossRefGoogle ScholarPubMed
Kang, H. J., Voleti, B., Hajszan, T., Rajkowska, G., Stockmeier, C. A., Licznerski, P., … Duman, R. S. (2012). Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nature Medicine, 18, 1413–1417. doi: 10.1038/nm.2886CrossRefGoogle ScholarPubMed
Kendler, K. S., Kessler, R. C., Walters, E. E., MacLean, C., Neale, M. C., Heath, A. C., & Eaves, L. J. (1995). Stressful life events, genetic liability, and onset of an episode of major depression in women. American Journal of Psychiatry, 152, 833–842. doi: 10.1176/ajp.152.6.833Google ScholarPubMed
Lagerberg, T., Fazel, S., Sjölander, A., Hellner, C., Lichtenstein, P., & Chang, Z. (2021). Selective serotonin reuptake inhibitors and suicidal behaviour: A population-based cohort study. Neuropsychopharmacology, 47, 817–823. doi: 10.1038/s41386-021-01179-z. Epub 2021 Sep 24.CrossRefGoogle ScholarPubMed
Leucht, S., Helfer, B., Gartlehner, G, & Davis, J. M. (2015). How effective are common medications: A perspective based on meta-analyses of major drugs. BMC Medicine, 13, 253. doi: 10.1186/s12916-015-0494-1CrossRefGoogle ScholarPubMed
Meyer, B. M., Rabl, U., Huemer, J., Bartova, L., Kalcher, K., Provenzano, J., … Pezawas, L. (2019). Prefrontal networks dynamically related to recovery from major depressive disorder: A longitudinal pharmacological fMRI study. Translational Psychiatry, 9, 64. doi: 10.1038/s41398-019-0395-8CrossRefGoogle ScholarPubMed
Pantazatos, S. P., Yttredahl, A., Rubin-Falcone, H., Kishon, R., Oquendo, M. A., Mann, J. J., & Miller, J. M. (2020). Depression-related anterior cingulate prefrontal resting state connectivity normalizes following cognitive behavioral therapy. European Psychiatry, 63, (1), e37. doi: 10.1192/j.eurpsy.2020.34CrossRefGoogle ScholarPubMed
Read, J., & Moncrieff, J. (2022). Depression: Why drugs and electricity are not the answer. Psychological Medicine, Apr 1, 1–3. doi: 10.1017/S0033291722000770. Online ahead of print.CrossRefGoogle ScholarPubMed
Sibille, E., Wang, Y., Joeyen-Waldorf, J., Gaiteri, C., Surget, A., Oh, S., … Lewis, D. A. (2009). A molecular signature of depression in the amygdala. American Journal of Psychiatry, 166, 1011–1024. doi: 10.1176/appi.ajp.2009.08121760CrossRefGoogle ScholarPubMed
UK ECT Review Group. (2002). Efficacy and safety of electroconvulsive therapy in depressive disorders: A systematic review and meta-analysis. The Lancet. Psychiatry, 361(9360), 799–808. doi: 10.1016/S0140-6736(03)12705-5Google Scholar